Skip to main content
Clinical Trials/NCT03497754
NCT03497754
Completed
Not Applicable

The Use of an External Ultrasound Fixator (ProbeFixR) on Intensive Care Patients, a Feasibility Study. (the Soundprobe Study)

Rijnstate Hospital1 site in 1 country10 target enrollmentStarted: May 17, 2018Last updated:
ConditionsHypovolemia

Overview

Phase
Not Applicable
Status
Completed
Sponsor
Rijnstate Hospital
Enrollment
10
Locations
1
Primary Endpoint
The correlation between the measurements done by FlotracR and TTE with and TTE without ProbeFixR

Overview

Brief Summary

Study to assess the feasibility of an external ultrasound fixator (ProbeFix)

Detailed Description

Rationale: Study to assess the feasibility of an external ultrasound fixator (ProbeFix) Objective: Cardiac output measurements using transthoracic ultrasound (TTE) with and without the use of the probeFixR will be evaluated in terms of accuracy. The TTE measurements will be combined with another form of cardiac output measurements (FlotracR) after a passive leg rasing (PLR) test.

Study design prospective, feasibility study Study population: Adult Intensive Care patients ( > 18 years)

Intervention (if applicable):

Consecutive adult patients on the ICU in which the FlotracR monitor is used will be evaluated after detection of hypovolemia.

Main study parameters/endpoints:

  • Percentage of patients in which the ProbeFixR can be used
  • The correlation between the measurements done by FlotracR and TTE with and TTE without ProbeFixR

Although no side effects are to be expected the investigators will monitor the patients after the ProbeFix is removed for any skin damage. The investigators will grade this damage into 3 categories:

  • No skin marks
  • Mild skin marks (no treatment necessary)
  • Severe skin marks (surgical or medical treatment necessary)
  • If the patients are awake the investigators will ask them whether they felt the ProbeFixR to be unpleasant on a scale of 0-10 (0 being: I did not feel anything and 10 being very unpleasant).

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult Intensive Care patients ( \> 18 years), with hypovolemia detected with Flotrac (SVV \> 10%)

Exclusion Criteria

  • Pregnancy
  • Atrial fibrillation or other irregular heart rhythm
  • Pulmonary edema
  • PLR not possible (eg neurological disease, spinal trauma, restricted limb movement, deep venous thrombosis, or any other reason as indicated by the attending intensivist).
  • age \< 18 years

Outcomes

Primary Outcomes

The correlation between the measurements done by FlotracR and TTE with and TTE without ProbeFixR

Time Frame: 8 weeks

A Bland and Altman plot will be constructed and the limits of agreement will be calculated.

Secondary Outcomes

  • Patients in which the ProbeFixR can be used(8 weeks)
  • Skin marks as possible side effect; scored as 'no skin marks', 'mild skin marks (no treatment necessary)' or 'severe skin marks (surgical or medical treatment necessary)'(8 weeks)
  • Is the Probefix unpleasant on a scale of 0-10(8 weeks)

Investigators

Sponsor
Rijnstate Hospital
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials